Jordyn Sava

The FDA recently approved Lu 177 vipivotide tetraxetan for use in patients with metastatic castration-resistant prostate cancer.

Pembrolizumab and MRx0518 has shown clinical benefit in patients with renal cell carcinoma that have progressed on a prior immune checkpoint inhibitor.

Treatment with AUTO1, an investigational CD19-targeted chimeric antigen receptor T-cell therapy, is being evaluated in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Venetoclax consolidation after 12-cycles of treatment increases the duration of known toxicities and does not prevent the loss of minimal residual disease response and subsequent risk of disease relapse in patients with previously untreated chronic lymphocytic leukemia, a study shows.

TST001 has shown to be safe in ongoing trials alone or in combination with chemotherapy and displayed encouraging anti-tumor activity signals in gastric cancer and other solid tumor patients expressing CLDN18.2.

The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.

In an interview with Targeted Oncology following the tweet chat, Yelena Y. Janjigian, discussed the key takeaways from the discussion and highlighted the biomarkers and standard of care for the patient in this case.

Lower rates of neutropenia and hypokalemia were also observed with maribavir than valganciclovir, ganciclovir, and foscarnet, and a lower proportion of HCT recipients discontinued treatment with maribavir than IAT.

Data from the SORAYA trial shows the use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer to result in meaningful anti-tumor activity, consistent safety, and favorable tolerability.

Pembrolizumab is now an FDA-approved treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Findings show adjuvant pembrolizumab to significantly improve disease-free survival in patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression

Orphan drug designation has been granted to TCB-002 for use as a potential therapeutic option in patients with relapsed/refractory acute myeloid leukemia.

In an interview with Targeted Oncology, Ghaith Abu-Zeinah, discussed the factors contributing to overall survival in patients with polycythemia vera and what is expected of future research.

The FDA has approved the FoundationOne CDx as a companion diagnostic to identify patients with non–small cell lung cancer with tumors that harbor EGFR exon 19 deletions or exon 21 substitutions.

Selinexor shows statistically significant improvement in progression-free survival in patients with endometrial cancer.

Type C meeting with the FDA requested by Allarity to discuss potential clinical paths to support approval of dovitinib as a potential option in the third-line treatment of patients with renal cell carcinoma

Relatlimab plus nivolumab demonstrated reduction in risk of progression or death and numerically improved overall survival compared to nivolumab alone.

Cabozantinib in combination with atezolizumab shows no effect on survival compared to sorafenib in patients with previously untreated advanced hepatocellular carcinoma based on results from the final analysis of the phase 3 COSMIC-312 trial.

Tracy Rose, MD, discussed the future of adjuvant and neoadjuvant therapy in muscle-invasive bladder cancer specifically using cisplatin-based regimens.

The FDA approved the BRACAnalysis CDx test for use as a companion diagnostic with adjuvant olaparib to identify patients with germline BRCA-mutated for patients with HER2 negative, high-risk early-stage breast cancer.

Ribociclib plus letrozole demonstrated statistically significant improvement in overall survival with the combination in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.

Orphan drug designation has been granted to HT-KIT from the FDA for the treatment of mastocytosis

In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD further discussed the results of the phase 2 trial of the combination of cabozantinib and nivolumab in patients with metastatic non-clear cell RCC and how it impacts the future of this space.

Pyrotinib combined with apecitabine demonstrated promising activity in patients with HER2-positive breast cancer that have brain metastases, according to findings from the prospective phase 2 PERMEATE study.

Significantly longer event-free survival was not demonstrated with tisagenlecleucel in the second-line setting when compared to standard-of-care second-line therapy in patients with refractory or early relapsed aggressive B-cell lymphoma.

Fast track designation has been granted to 7HP349, in combination with a CTLA-4 inhibitor for the treatment of patients with unresectable or metastatic malignant melanoma following treatment failure with a PD-1 inhibitor.

Srdan Verstovsek, MD, discussed the ways in which ropeginterferon and rusfertide can reduce thromboembolic events in polycythemia vera.

Updated data from the ongoing phase 1b/2 trial of batiraxcept in combination with cabozantinib shows favorable outcomes in patients with clear cell renal cell carcinoma.

In an interview with Targeted Oncology, David Siegel, MD, explained the many changes seen in pediatric cancer mortality and survival over the past 40 years.

In an interview with Targeted Oncology, Ryan Sugarman, MD, discussed the CheckMate 649 trial and Q-TWiST results to provide a further understanding of survival and quality of life benefit of nivolumab plus chemo versus chemo alone.